ClinicalTrials.gg
Not yet recruitingNCT07399600P-TMS MetALDUpdated Feb 10, 2026

Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease

An interventional study of Individually Targeted rTMS and Conventional rTMS in Liver Diseases, Alcoholic, Fatty Liver and Metabolic Syndrome, sponsored by The Affiliated Hospital of Hangzhou Normal University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by The Affiliated Hospital of Hangzhou Normal University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique, works to treat Metabolic dysfunction-associated and alcohol-associated liver disease (MetALD). The main questions it aims to answer are:

  • Can rTMS effectively treat MetALD?
  • Is an individualized, precision-targeted rTMS approach more effective than the standard rTMS method?
  • What changes in brain activity are associated with the treatment?

Researchers will compare three different types of stimulation:

  • Group A: Individualized rTMS targeting a deep brain reward area (the Nucleus Accumbens) based on each participant's brain scan (fMRI).
  • Group B: Standard rTMS applied using the traditional "5 cm" rule for positioning.
  • Group C: Sham (placebo) rTMS, which mimics the procedure but delivers no significant magnetic stimulation.

Participants will:

  • Be randomly assigned to one of the three groups (A, B, or C).
  • Undergo an MRI brain scan before starting treatment.
  • Receive a total of 20 rTMS sessions, completing at least 4 sessions per week.
  • Have additional MRI scans and clinical assessments halfway through and immediately after the treatment course.
  • Attend follow-up visits at 1, 3, and 6 months after treatment completion to assess long-term effects.
02

Conditions studied

  • Liver Diseases, Alcoholic
  • Fatty Liver
  • Metabolic Syndrome

Keywords

  • Liver Diseases, Alcoholic
  • Fatty Liver
  • Metabolic Syndrome
  • Transcranial Magnetic Stimulation
  • Randomized Controlled Trial
03

In context

Liver Diseases, Alcoholic

74 studies on the registry are indexed under Liver Diseases, Alcoholic; 25 are open to participants now.

This study's planned enrollment of 105 is above the median of 90 across 44 interventional studies indexed under Liver Diseases, Alcoholic.

Browse Liver Diseases, Alcoholic studies →

Lead sponsor

The Affiliated Hospital of Hangzhou Normal University is the lead sponsor of 11 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants are able to understand the study protocol, requirements, and restrictions, are fully informed of potential adverse events, are willing to comply with follow-up visits, and voluntarily sign the form before enrollment.
  • Meet the diagnostic criteria for MASLD according to the Guidelines for the Prevention and Treatment of Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition), and fulfill the European definition of MetALD with moderate alcohol consumption (20-50 g/day for women; 30-60 g/day for men).
  • Age between 18 and 65 years.
  • (BMI) > 24 kg/m².
  • No history of alcohol abuse.

Exclusion criteria

Exclusion Criteria:

  • to magnetic resonance imaging (MRI) or transcranial magnetic stimulation (TMS).
  • Mild cognitive impairment, defined as (MoCA) score \< 25.
  • Severe comorbid somatic diseases or neurological disorders.
  • History of psychiatric disorders, or current use of antipsychotic medications.
  • Pregnant or breastfeeding women, or those planning pregnancy.
  • Previous TMS treatment within the last 3 months.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Active comparator
    Conventional rTMS

    Device: Conventional rTMS

  • Sham comparator
    Sham rTMS

    Device: Transcranial Magnetic Stimulation Sham

  • Experimental
    Active rTMS

    Device: Individually Targeted rTMS

Interventions

  • DeviceIndividually Targeted rTMS

    Participants will receive individualized transcranial magnetic stimulation (TMS) based on neuroimaging-guided localization of the nucleus accumbens (NAc). After the first MRI scan, participants will be randomized by an independent researcher responsible for data analysis. The individualized stimulation coordinates will be provided to the TMS operator before treatment. Intervention will be delivered using intermittent theta-burst stimulation (iTBS): the coil will be placed tangentially to the scalp over the individualized target. Stimulation parameters: 90% resting motor threshold (RMT); bursts of 3 pulses at 50 Hz; bursts repeated at 5 Hz; a total of 1800 pulses per session; stimulation duration 570 seconds. Each participant will receive 20 sessions in total, with at least 2 treatment days per week (2 sessions/day, 4 sessions/week). MRI and clinical assessments will be repeated at mid-treatment and after treatment completion, with follow-up clinical evaluations at 1, 3, and 6 months.

  • DeviceConventional rTMS

    Conventional rTMS is applied to the left dorsolateral prefrontal cortex (DLPFC) using the standard 5 cm rule for scalp-based localization. Stimulation is delivered with intermittent theta-burst stimulation (iTBS) at 90% resting motor threshold (RMT), 3 pulses at 50 Hz per burst, repeated at 5 Hz, for a total of 1800 pulses per session. Each session lasts about 570 seconds. Participants complete 20 sessions over 4 weeks, with 2 sessions per day on 2 days per week.

  • DeviceTranscranial Magnetic Stimulation Sham

    Sham rTMS is delivered using a sham coil or low-intensity stimulation (10% RMT) to mimic the clicking sounds and scalp sensations of active rTMS without producing cortical activation. The sham sessions are matched to the active treatment in frequency, duration, and total number: 20 sessions in 4 weeks (2 sessions/day, 2 days/week, 570 seconds per session).

06

What researchers measure

Primary outcomes

  1. Percent Change in Liver Fat Content (LFC) From Baseline to End of Treatment as Measured by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF)

    Time frame: From baseline to the end of treatment (Week 4)

Secondary outcomes

  1. Change in Controlled Attenuation Parameter (CAP, dB/m) From Baseline as Assessed by Vibration-Controlled Transient Elastography (FibroScan® VCTE)

    Time frame: From baseline to mid-treatment (Week 2), end of treatment (Week 4), and at 1-, 3-, and 6-month follow-up

  2. Change in Liver Stiffness Measurement (LSM, kPa) From Baseline as Assessed by FibroScan® VCTE

    Time frame: From baseline to mid-treatment (Week 2), end of treatment (Week 4), and at 1-, 3-, and 6-month follow-up

  3. LFC From Baseline as Measured by MRI-PDFF

    Time frame: From baseline to the end of treatment (Week 4)

  4. Proportion of Participants Achieving ≥30% or ≥50% Reduction in LFC From Baseline

    Time frame: From baseline to the end of treatment (Week 4)

  5. Change in Serum Levels of Liver Enzymes (ALT, AST, ALP, GGT [U/L]) From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  6. Change in Serum Level of Albumin From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  7. Change in International Normalized Ratio (INR) From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  8. Change in Prothrombin Time (PT) From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  9. Change in Serum Level of Total Bilirubin (TBIL) From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  10. Proportion of Participants With ALT Reduction >17 U/L From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  11. Change in Glucose Metabolism Markers (HOMA-IR [Index]; HOMA-β [Index]) From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  12. Change in Glucose Metabolism Markers (HbA1c [%]) From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  13. Change in Fasting Plasma Glucose (FPG) From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  14. Change in Fasting Insulin From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  15. Change in Concentration of Conventional Lipid Panel (TC, TG, HDL-C, LDL-C, non-HDL-C, VLDL-C [mmol/L]) From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  16. Change in Concentration of Apolipoproteins (Apo A1, Apo B [g/L]) From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  17. Change in Serum Lipoprotein(a) (Lp(a)) Concentration From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  18. Change in Serum Free Fatty Acids (FFA) Concentration From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  19. Change in Body Weight [kg] From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  20. Change in BMI [kg/m²] From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  21. Change in Body Circumferences (Waist, Hip) [cm] From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  22. Change in Waist-to-Hip Ratio From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  23. Change in General Food Craving Questionnaire-Trait (G-FCQ-T) Total Score From Baseline

    G-FCQ-T The General Food Craving Questionnaire-Trait (G-FCQ-T) is a self-reported instrument used to assess the general tendency to experience food cravings. It comprises 21 items. Participants rate each item on a 6-point Likert scale ranging from 1 ("Never") to 6 ("Always"). The total score is the sum of all item ratings, with a possible range from 21 to 126. A higher total score indicates a more severe trait propensity for food craving.

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  24. Change in General Food Craving Questionnaire-State (G-FCQ-S) Total Score From Baseline

    G-FCQ-S The General Food Craving Questionnaire-State (G-FCQ-S) is a self-reported instrument used to assess the current, momentary state of food craving. It comprises 15 items. Participants rate each item on a 6-point Likert scale ranging from 1 ("Strongly Disagree") to 6 ("Strongly Agree"). The total score is the sum of all item ratings, with a possible range from 15 to 90. A higher total score indicates a more intense current state of food craving.

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  25. Change in Score on Visual Analogue Scale (VAS) for Subjective Food Craving From Baseline

    Subjective food craving is assessed using a Visual Analogue Scale (VAS). Participants indicate their current, momentary level of food craving by marking a point on a 100-mm horizontal line. The left endpoint (0 mm) is labeled "No food craving at all," and the right endpoint (100 mm) is labeled "The most intense food craving imaginable." The score is determined by measuring the distance from the left endpoint to the participant's mark, ranging from 0 to 100. A higher score indicates a more intense subjective feeling of food craving.

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  26. Change in Caloric intake recorded by the Mint Health App From Baseline

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  27. Change in Alcohol Use Disorders Identification Test (AUDIT) Score From Baseline

    The Alcohol Use Disorders Identification Test (AUDIT) is a simple, self-reported screening tool developed by the World Health Organization (WHO) to identify hazardous and harmful patterns of alcohol consumption. The questionnaire consists of 10 items. The first 8 items are scored on a scale from 0 to 4. Items 9 and 10 are scored 0, 2, or 4. The total score is the sum of all item ratings, with a possible range from 0 to 40. A higher total score indicates a greater likelihood of hazardous and harmful alcohol use, as well as possible alcohol dependence.

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  28. Change in Penn Alcohol Craving Scale (PACS) Score From Baseline

    The Penn Alcohol Craving Scale (PACS) is a self-reported questionnaire designed to measure the intensity of an individual's craving for alcohol over the past week. The scale consists of 5 items assessing the frequency, duration, and intensity of craving, the ability to resist drinking, and the overall rating of craving. Each item is rated on a 6-point scale from 0 to 6, with varying verbal anchors for each item (e.g., "Never" to "Nearly All the Time"). The total score is the sum of all 5 item ratings, with a possible range from 0 to 30. A higher total score indicates a more severe level of subjective alcohol craving.

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

  29. Change in Alcohol Consumption Assessed by the Timeline Followback (TLFB) Method From Baseline

    Alcohol consumption is assessed using the Timeline Followback (TLFB) method, a structured interview that provides a quantitative estimate of an individual's daily drinking. Using a calendar to aid recall, participants retrospectively report their daily alcohol consumption over a specified period (e.g., the past 30 days). The data is used to calculate key metrics such as the number of drinking days, the number of heavy drinking days, and the average number of standard drinks consumed per day or per week. A higher value indicates a greater level of alcohol consumption.

    Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months

Other outcomes

  1. Resting-State Functional Connectivity (rs-FC) Measured by fMRI

    Resting-state functional connectivity (rs-FC) will be assessed using functional magnetic resonance imaging (fMRI). This measures the temporal correlation of spontaneous brain activity between different neural regions, forming functional networks (e.g., Default Mode Network, Executive Control Network). The strength of connectivity is represented by correlation coefficients (z-values). A higher absolute value indicates stronger functional connectivity.

    Time frame: From baseline to mid-treatment (Week 2) and end of treatment (Week 4)

  2. Amplitude of Low-Frequency Fluctuations (ALFF) Measured by fMRI

    The amplitude of low-frequency fluctuations (ALFF) will be calculated from resting-state fMRI data. It measures the intensity of spontaneous neural activity in specific brain regions. The value is typically presented as a normalized Z-score. A higher ALFF value indicates greater regional spontaneous neural activity.

    Time frame: From baseline to mid-treatment (Week 2) and end of treatment (Week 4)

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Aug 2027, 18 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Feb 10, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07399600
Lead sponsor
The Affiliated Hospital of Hangzhou Normal University
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Junping Shi
Contact
20131004@hznu.edu.cn
+86 13957121199

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion